[go: up one dir, main page]

MA45202A1 - Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation - Google Patents

Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation

Info

Publication number
MA45202A1
MA45202A1 MA45202A MA45202A MA45202A1 MA 45202 A1 MA45202 A1 MA 45202A1 MA 45202 A MA45202 A MA 45202A MA 45202 A MA45202 A MA 45202A MA 45202 A1 MA45202 A1 MA 45202A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
receptor antagonist
mineralocorticoid receptor
treatment
kidney disease
Prior art date
Application number
MA45202A
Other languages
English (en)
Other versions
MA45202B1 (fr
Inventor
Zhenhua Huang
Xiaocui Guo
Original Assignee
Kbp Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61689352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA45202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kbp Biosciences Co Ltd filed Critical Kbp Biosciences Co Ltd
Publication of MA45202A1 publication Critical patent/MA45202A1/fr
Publication of MA45202B1 publication Critical patent/MA45202B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation. Par administration orale d'une composition pharmaceutique à un patient souffrant d'une maladie rénale chronique nécessitant un tel traitement, une asc efficace et sûre de la composition pharmaceutique va de 188 ng*h/ml à 3173 ng*h/ml, avec une biodisponibilité chez les mammifères = 50 %. L'asc est régulée dans une plage sûre et efficace lorsque la composition pharmaceutique est administrée pour le traitement d'une maladie rénale chronique dans une dose quotidienne de 0,1 mg à 1,0 mg.
MA45202A 2016-09-24 2017-09-22 Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation MA45202B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610849142 2016-09-24
PCT/CN2017/102969 WO2018054357A1 (fr) 2016-09-24 2017-09-22 Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation

Publications (2)

Publication Number Publication Date
MA45202A1 true MA45202A1 (fr) 2020-11-30
MA45202B1 MA45202B1 (fr) 2022-04-29

Family

ID=61689352

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45202A MA45202B1 (fr) 2016-09-24 2017-09-22 Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation

Country Status (29)

Country Link
US (2) US11806344B2 (fr)
EP (1) EP3517113A4 (fr)
JP (2) JP7090599B2 (fr)
KR (1) KR102226516B1 (fr)
CN (1) CN109069502B (fr)
AU (1) AU2017329549B2 (fr)
BR (1) BR112019005214A2 (fr)
CA (1) CA3037588C (fr)
CL (1) CL2019000753A1 (fr)
CO (1) CO2019003808A2 (fr)
CR (2) CR20190203A (fr)
CU (1) CU24569B1 (fr)
DO (1) DOP2019000072A (fr)
EA (1) EA201990668A1 (fr)
EC (1) ECSP19027578A (fr)
IL (1) IL265560B (fr)
MA (1) MA45202B1 (fr)
MX (1) MX391602B (fr)
MY (1) MY195054A (fr)
NZ (1) NZ751901A (fr)
PE (1) PE20190608A1 (fr)
PH (1) PH12019500516A1 (fr)
RU (2) RU2725153C1 (fr)
SG (1) SG10201912389WA (fr)
TN (1) TN2019000063A1 (fr)
TW (2) TWI780488B (fr)
UA (1) UA123464C2 (fr)
WO (1) WO2018054357A1 (fr)
ZA (1) ZA201901740B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA45202B1 (fr) 2016-09-24 2022-04-29 Kbp Biosciences Co Ltd Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
CN113425683B (zh) * 2021-08-19 2022-09-20 谢彩华 一种三氮脒缓释注射剂及其制备方法
CN116492336B (zh) * 2023-04-04 2024-07-05 迪沙药业集团有限公司 一种坎地沙坦酯药物组合物
CN120168468B (zh) * 2025-03-05 2025-10-17 苏州天马医药集团天吉生物制药有限公司 一种非奈利酮制剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
JP5846647B2 (ja) * 2010-02-25 2016-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン製剤
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
SI2632451T1 (en) * 2010-10-29 2018-02-28 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
ES2897496T3 (es) * 2012-12-22 2022-03-01 Kbp Biosciences Pte Ltd Procedimiento para la preparación de un compuesto usado como antagonista del receptor de mineralocorticoides
MA45202B1 (fr) 2016-09-24 2022-04-29 Kbp Biosciences Co Ltd Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation

Also Published As

Publication number Publication date
IL265560B (en) 2022-07-01
US20240016796A1 (en) 2024-01-18
RU2020120876A3 (fr) 2020-12-28
WO2018054357A1 (fr) 2018-03-29
MA45202B1 (fr) 2022-04-29
JP7090599B2 (ja) 2022-06-24
CA3037588A1 (fr) 2018-03-29
RU2725153C1 (ru) 2020-06-30
JP2022037044A (ja) 2022-03-08
TW201813645A (zh) 2018-04-16
EA201990668A1 (ru) 2019-10-31
AU2017329549A1 (en) 2019-04-11
CL2019000753A1 (es) 2019-07-19
MX391602B (es) 2025-03-21
MY195054A (en) 2023-01-05
UA123464C2 (uk) 2021-04-07
DOP2019000072A (es) 2019-06-16
EP3517113A4 (fr) 2020-07-08
PH12019500516A1 (en) 2020-02-24
CN109069502B (zh) 2021-08-06
CU20190023A7 (es) 2019-11-04
RU2020120876A (ru) 2020-08-26
CR20190203A (es) 2019-06-26
TN2019000063A1 (en) 2020-07-15
CU24569B1 (es) 2022-01-13
HK1258622A1 (zh) 2019-11-15
IL265560A (en) 2019-05-30
CO2019003808A2 (es) 2019-04-30
ECSP19027578A (es) 2019-07-31
AU2017329549B2 (en) 2020-05-14
CN109069502A (zh) 2018-12-21
JP2019532939A (ja) 2019-11-14
BR112019005214A2 (pt) 2019-06-11
CR20240015A (es) 2024-04-05
EP3517113A1 (fr) 2019-07-31
MX2019003339A (es) 2019-06-03
TWI715806B (zh) 2021-01-11
RU2750667C2 (ru) 2021-06-30
TW202100156A (zh) 2021-01-01
CA3037588C (fr) 2022-07-12
ZA201901740B (en) 2019-10-30
SG10201912389WA (en) 2020-02-27
PE20190608A1 (es) 2019-04-23
US11806344B2 (en) 2023-11-07
TWI780488B (zh) 2022-10-11
KR20190057323A (ko) 2019-05-28
NZ751901A (en) 2021-07-30
US20190201390A1 (en) 2019-07-04
KR102226516B1 (ko) 2021-03-12

Similar Documents

Publication Publication Date Title
RU2470642C2 (ru) Аналоги птерина для лечения состояния, чувствительного к вн4
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA45202A1 (fr) Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
JP6837486B2 (ja) 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法
MA43817B1 (fr) Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2
MA50201B1 (fr) Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
MA30539B1 (fr) Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38.
MA62992B1 (fr) Formulations de capsules
JP2019530706A5 (fr)
MA46342B1 (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MA45625A (fr) Nouveaux régimes posologiques pour conjugués anticorps-médicaments à base d'anticorps anti-axl
JP2019507786A5 (fr)
MA39421A (fr) Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes
JP2016528171A5 (fr)
MA50247A (fr) Compositions aqueuses comprenant de la bilastine et du mométasone
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
CA3156182A1 (fr) Procedes de traitement d'etats lies au recepteur s1p1
EP3795170C0 (fr) Composition pharmaceutique comprenant du ccn5 utilisé comme ingrédient efficace pour la prévention ou le traitement d'une maladie rétinienne
MA57828B1 (fr) Combinaisons du masupirdine avec du donépézil ou de la mémantine pour le traitement de symptômes comportementaux et psychologiques chez des patients atteints de démence
MA43793B1 (fr) Procédé de préparation de formulations solides de mésalazine
MA53513B1 (fr) Combinaison à dose fixe et à libération immédiate de mémantine et de donépézil
RU2019140198A (ru) Способ применения элементарной ртути для лечения онкологических заболеваний
TH1901001650A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบรวมด้วยมิเนอรัลโลคอร์ติคอยด์รีเซ็ปเตอร์แอนตาโกนิสต์และการใช้สารดังกล่าว
JPWO2016148261A1 (ja) レビー小体病の治療および／または予防剤